Alvotech ALVO
NASDAQ · United States · Health Technology
$5.52-0.29 (-4.91%)
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · USD · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
The biotech company’s stock rises after Barclays gives it a double upgrade, citing confidence in upcoming FDA approvals.
Barclays analyst Glen Santangelo raised the stock to Overweight from Underweight and lifted his target to $8 from $4.
Alvotech (NASDAQ:ALVO) shares gained 5. 6% in premarket trading after Barclays upgraded the biosimilar drug developer from Underweight to Overweight and raised its price target from $4.
REYKJAVIK, Iceland, August 31, 2026 - Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review a Biologics License Application (BLA) for AVT80, a proposed interchangeable biosimilar to Entyvio® (vedolizumab) prefilled syringe and autoinjector for subcutaneous administration. Under a partnership with Teva
Alvotech stock has fallen about 50% over the past three years, yet the valuation checks currently lean cheap and the market is reacting positively to fresh licensing deals and regulatory progress. Over the past three years the share price is down about 50%, which means any case for owning Alvotech today rests heavily on a potential recovery from a deep drawdown. A recent licensing agreement with Lotus Pharmaceutical for two biosimilars and ongoing work toward U.S. approvals can support...
In August 2026, Alvotech announced a licensing and commercialization agreement with Lotus Pharmaceutical for biosimilar candidates AVT34 (Imfinzi) and AVT87 (Hemlibra) across the United States and eight Asian markets, with potential consideration of up to approximately US$150 million plus ongoing supply revenues. The deal expands Alvotech’s access to oncology and hematology markets while keeping it in control of development, regulatory approvals, and global product supply. We’ll now examine...
A major Wall Street firm says a regulatory shift and coming launches could change the setup for one biosimilar developer.
REYKJAVIK, ICELAND (August 27, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Robert Wessman, Founder and Chairman, and Dr. Balaji V. Prasad, Chief Strategy Officer, will participate in the upcoming investor conferences in September as follows: Morgan Stanley 24th Annual Global Healthcare Conference in New York – Fireside chat on Tuesday, September 15, 2
Alvotech (NASDAQ:ALVO) extended its winning streak to a 5th consecutive day on Monday, jumping 18.51 percent to finish at $5.25 apiece, after the Bank of America (BofA) raised its price target for the company. In its recent coverage, BofA initiated a buy recommendation on Alvotech shares with a price target of $7, amid the closure […]
Investing.com -- BofA Securities initiated coverage of Alvotech S.A. with a “buy” rating and a $7 price objective, versus the stock’s $4.43 price as of Monday, after the FDA’s closure of its inspection of the company’s Reykjavik manufacturing facility removed a key regulatory overhang and as the biosimilar developer enters what BofA called its most meaningful launch cycle since inception.
REYKJAVIK, ICELAND (August 21, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical (TWSE Stock Code: 1795) covering two of Alvotech’s candidates in the United States and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to H
Moby summary of Alvotech's Q2 2026 earnings call
REYKJAVIK, ICELAND (August 19, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced financial results for the first half of 2026 and provided a business update. A supplemental long‑form earnings release and management presentation providing additional details and business update is available on our website: https://alvotech.com/financi
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.